Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

6 september 2018 uppdaterad av: Eisai Inc.

A Multicenter Phase 0 Study In Healthy Subjects and Subjects With Either Hepatic Or Renal Impairment To Obtain Plasma For Assessment In Vitro Lenvatinib Protein Binding

E7080-A001-010 is a multicenter, parallel-group study in participants with mild, moderate, or severe hepatic or renal impairment and age-, gender-, and smoking status-matched healthy participants. The primary objective of the study is to obtain plasma from participants for use in in vitro protein binding studies.

Studieöversikt

Status

Avslutad

Intervention / Behandling

Detaljerad beskrivning

E7080-A001-010 is a multicenter, parallel-group study in participants with mild, moderate, or severe hepatic or renal impairment and age-, gender-, and smoking status-matched healthy participants. Approximately 6 participants with each degree (mild, moderate, or severe) of hepatic or renal impairment will be enrolled. Two cohorts of 8 healthy participants will be enrolled. One cohort of healthy participants will be matched to the hepatic-impaired participants, whereas the other will be matched to the renal-impaired participants.

The study has 2 phases. The Pre-study Phase consists of a Screening Period and a Baseline Period. The Study Phase consists of a 2-day Study Period. No lenvatinib will be administered in this study.

The end of the study will be the date of the last study visit for the last participant in the study.

The following estimates are provided:

  • From first participant in to last participant out, the study is expected to take approximately one year to complete.
  • The maximum estimated duration of the study for each participant is anticipated to be approximately 5 weeks.

Studietyp

Interventionell

Inskrivning (Faktisk)

54

Fas

  • Tidig fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Florida
      • Orlando, Florida, Förenta staterna
        • Orlando Clinical Research Center, Inc.
    • Minnesota
      • Minneapolis, Minnesota, Förenta staterna
        • Davita Clinical Research
    • Tennessee
      • Knoxville, Tennessee, Förenta staterna
        • New Orleans Center for Clinical Research

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 79 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

Key Inclusion Criteria:

  • Male or Female
  • Age, at the time of Informed Consent:

    i. Hepatic Impairment Participants (Including Matched Healthy Participants): 18 to 70 years old, inclusive ii. Renal Impairment Participants (Including Matched Healthy Participants): 18 to 79 years old, inclusive

  • Non-smokers and smokers who smoke no more than 10 cigarettes per day
  • Besides diabetes and, as appropriate, renal or hepatic impairment, participants must have no history of acute or chronic clinically relevant disease or condition, as determined by the investigator.
  • For participants with hepatic impairment:

    • Liver cirrhosis that has been stable;
    • Platelet count >30,000 cells/millimeter cubed (mm^3);
    • Total score on the Child-Pugh classification system between 5 and 6 (Group 1, mild), 7 and 9 (Group 2, moderate), and 10 and 15 (Group 3, severe)
  • For healthy participants:

    • Creatinine clearance ≥ 81 milliliter per minute (mL/min)

  • For participants with renal impairment:

    • Must have a diagnosis of renal impairment that has been stable
    • Must have renal impairment in the following categories based on creatinine clearance values: mild (creatinine clearance, 50 to 80 mL/min), moderate (creatinine clearance, 30 to 49 mL/min), or severe (creatinine clearance, 15 to 29 mL/min) renal impairment

Exclusion Criteria:

Key Exclusion Criteria:

  • Use of any new medication
  • Human immunodeficiency virus (HIV) positive
  • Presence of acute active liver disease or acute liver injury
  • History of significant cardiovascular impairment
  • Positive drug or alcohol test
  • Weight loss or gain of >10% prior to Day 1
  • Receipt of blood or blood products or donation of blood or blood products

For participants with hepatic impairment:

  • History of hepatic transplant, systemic lupus erythematosus, or hepatic coma
  • Received treatment with interferon or pegylated interferon
  • Participants who have encephalopathy >Grade 2, sepsis, or gastrointestinal bleeding; esophageal varices >Grade 2, acute hepatic failure of any etiology, history of surgical portosystemic shunt, renal impairment (creatinine clearance <50 mL/min according to the Cockcroft-Gault formula), and rapidly deteriorating hepatic function
  • Systolic blood pressure (SBP) ≥ 160 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) ≥ 100 mmHg

For healthy participants:

• Hemoglobin level less than 12.0 grams per deciliter (g/dL)

For participants with renal impairment:

  • A history of renal transplant
  • SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg for participants with mild renal impairment; SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg for participants with moderate and severe renal impairment
  • Significant bleeding diathesis

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Övrig: 6 participants with mild renal impairment
Renal Impairment Mild: creatinine clearance, 50 to 80 milliliters per minute (mL/min)
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Övrig: 6 participants with moderate renal impairment
Renal Impairment Moderate: creatinine clearance, 30 to 49 mL/min
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Övrig: 6 participants with severe renal impairment
Renal Impairment Severe: creatinine clearance, 15 to 29 mL/min
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Övrig: 8 participants normal renal status
Renal status normal as defined by creatinine clearance ≥ 81 mL/min, otherwise age, gender, and smoking characteristics matching renal-impaired participants
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Övrig: 6 participants with mild hepatic impairment
Hepatic impairment mild: total score on the Child-Pugh classification system between 5 and 6
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Övrig: 6 participants with moderate hepatic impairment
Hepatic impairment moderate: total score on the Child-Pugh classification system between 7 and 9
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Övrig: 6 participants with severe hepatic impairment
Hepatic impairment severe: total score on the Child-Pugh classification system between 10 and 15
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Övrig: 8 participants normal hepatic status
Hepatic status normal, otherwise age, gender, and smoking characteristics matching hepatic-impaired participants
No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Number of participants with any serious adverse event and any non-serious adverse event
Tidsram: 1 week
1 week

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

2 december 2016

Primärt slutförande (Faktisk)

8 juli 2017

Avslutad studie (Faktisk)

8 juli 2017

Studieregistreringsdatum

Först inskickad

16 december 2016

Först inskickad som uppfyllde QC-kriterierna

19 december 2016

Första postat (Uppskatta)

20 december 2016

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

7 september 2018

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 september 2018

Senast verifierad

1 september 2018

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • E7080-A001-010

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Hepatic Impairment; Renal Impairment

Kliniska prövningar på Plasma Sampling

3
Prenumerera